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Abstract
We aimed to determine the duration of faecal carriage of extended-spectrum b-lactamase (ESBL) -producing Enterobacteriaceae (EPE) in
patients with clinical infection caused by an EPE, to study host strains during carriage, and to identify factors associated with prolonged
carriage. Patients (n = 61) were followed with faecal samples and questionnaires about antimicrobial treatment and risk factors for EPE, 1, 3,
6 and 12 months after EPE infection. The EPE isolates were subjected to ESBL genotyping, epidemiological typing with pulsed-ﬁeld gel
electrophoresis and PCR-based replicon typing. Escherichia coli isolates were analysed with PCR for phylogrouping, detection of pabB
(ST131) and virulence content. Patient-related and strain-related variables were compared for carriers and non-carriers at 12 months.
Carriage of EPE was observed in 51 of 61 (84%) patients after 1 month, 36 of 61 (66%) after 3 months, 31 of 61 (55%) after 6 months and
26 of 61 (43%) after 12 months. Of the 26 carriers at 12 months, ﬁve had previous negative samples. In 17 of 61 patients, ESBL was found in
a new bacterial species and/or strain during carriage. Among E. coli, 14 of 49 belonged to the international clone ST131. Phylogroup B2 and
CTX-M-gr.-9 were associated with being carriers at 12 months (OR 4.3, 95% CI 1.1–16.3 and OR 6.4, 95% CI 1.3–30.9, respectively). In
conclusion, EPE carriage is common 12 months after infection and persisting carriage may be associated with E. coli phylogroup B2 and
CTX-M-gr.-9. The host strain frequently changes throughout carriage and negative samples do not imply eliminated carriage.
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Introduction
Extended-spectrum b-lactamase (ESBL) -producing Escherichia
coli and Klebsiella pneumoniae have become important causes of
nosocomial and community-acquired infections, and high
numbers of ESBL carriers among healthy individuals have been
reported from several countries [1]. The rapid increase of
CTX-M-15 among ESBL-producing E. coli is largely linked to
the internationally spread E. coli clone ST131-O25b [2].
Comorbidities, use of antimicrobial agents and hospital contact
are well-known risk factors for community-onset infections
with ESBL-producing Enterobacteriaceae (EPE) [1], but trans-
mission of EPE within households outweighs nosocomial
dissemination in the non-outbreak setting [3].
Although the prevalence and risk factors for EPE carriage
have been studied, little is known about the time course of
stool colonization. Previous reports show that EPE carriage
often persists for 3 months and may be prolonged by antibiotic
treatment [4]. In other studies, 51.5% were EPE carriers after
6 months (22nd European Congress of Clinical Microbiology
and Infectious Diseases, poster 1673), 20% after 12 months,
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but <5% after 2 years [5]. Persisting carriage of K. pneumoniae
carbapenemase-producing K. pneumoniae was recently associ-
ated with catheter use, low functional status and long-term
care facility stay [6].
Non-ESBL E. coli strains differ widely in their capacity to
colonize the colon, and this capacity is linked to virulence
factors associated with uropathogenicity [7]. Genes encoding P
ﬁmbriae, type 1 ﬁmbriae and other virulence factors are
enriched in resident strains, and there seems to be an additive
effect of these factors promoting persistence [7–9]. Strains
belonging to phylogroups B2 and D have an enhanced ability to
persist in the intestinal microbiota [7]. How pathogen-related
factors impact the duration of carriage of EPE is unknown.
ESBL genes are often located on conjugative plasmids
belonging to the IncF group [10,11], I1, N and K, with high
potential of recombination [12]. It is therefore likely that ESBL
enzymes are transferred from transient strains to resident
strains in the normal intestinal microbiota. However, knowl-
edge about transfer of ESBL enzymes between different strains
and species during the course of ESBL carriage is limited.
We present prospective data on the duration of faecal
carriage of EPE after ﬁrst-time EPE infection, and identify
patient and strain factors associated with prolonged carriage.
We also report on changes in host strains throughout the
carriage, and present data on plasmid replicon content for
cases for which the ESBL production was detected in a new
strain or species during the course of carriage.
Materials and Methods
Study design, outcome measures and deﬁnitions
The study was designed as a prospective cohort study.
Sixty-one patients were subjected to follow up with faecal
samples and questionnaires about antimicrobial treatment and
risk factors for EPE infection at 1, 3, 6 and 12 months after
diagnosis. The study outcome was faecal carriage of EPE.
Prolonged carriage was deﬁned as the ﬁnding of EPE in faeces
at 12 months.
Study population
The Karolinska University Hospital laboratory covers 80% of
the Stockholm County population. In 2009 the proportions of
ESBL-producing E. coli and K. pneumoniae in Stockholm were
3.3% and 2.8% [13]. The incidence of EPE infections was 40/
100 000 inhabitants [14].
All patients’ clinical isolates of EPE detected at Karolinska
University Hospital between February and December 2009
were identiﬁed (n = 508). Patients that were likely to be able
to understand instructions in Swedish and that would be able
to perform self-collection and submission of faecal samples
were eligible for inclusion. Since EPE was notiﬁable and was
still rare in Sweden at the time of the study, the regional
research ethics committee requested that the patients’
physicians were contacted to obtain approval to contact the
patients. Reasons for exclusion are shown in the Supporting
information (Fig. S1). Seventy-one patients were included.
Nine were lost to follow-up and one patient died. Character-
istics of the patients included and not included in analyses are
presented in Table 1.
Collection of samples and clinical data
At the speciﬁed time-points, 1, 3, 6 and 12 months after the
patients’ diagnosis with EPE infection, self-collected faecal
samples were obtained. At 1 month the patients ﬁlled in a
questionnaire about antimicrobial treatment received and
previously described risk factors for EPE infection (antimicro-
bial treatment, hospital stay, urinary catheter, travel abroad and
hospital admissions abroad within 6 months before the EPE
infection, and abnormalities of the urinary tract). At months 3, 6
and 12 the patients ﬁlled in a questionnaire about new acquired
infections and recently received antimicrobial treatment.
TABLE 1. Characteristics of 508 patients with extended spectrum b-lactamase-producing Enterobacteriaceae detected at the clinical
microbiology laboratory at Karolinska University Hospital between February and December 2009a
All patients (n = 508)
Patients included in
analyses (n = 61)
Patients not included in
analyses (n = 447) p value
Female 337 (66) 38 (61) 299 (67) 0.48
Age (mean) 57.8 58.3 57.7 0.87
Level of care
Hospital inpatients 308 (60) 35 (57) 273 (61) 0.002
Hospital outpatients 50 (10) 14 (23) 36 (8)
Long-term care facilities 25 (5) 0 25 (6)
Primary care 125 (25) 12 (20) 113 (25)
Culture material
Urine 437 (86) 51 (84) 386 (86) 0.39
Blood 24 (5) 5 (8) 19 (4)
Other 47 (9) 5 (8) 42 (9)
aData presented as number and column percentage in parenthesis if not otherwise stated.
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Processing of faecal samples and conﬁrmation of ESBL
production
EPE in the faecal samples were detected with ChromID
ESBL agar (bioMerieux, Craponne, France). Plates were
streaked with transport swabs (Copan, Brescia, Italy)
without previous broth enrichment. Unique colony morpho-
logies were studied with species identiﬁcation and antimi-
crobial susceptibility testing, using VITEK2 (bioMerieux).
Normally one to three colonies representing each colony
morphology were picked. ESBL production was conﬁrmed
with ESBL combination disks (Becton Dickinson, Franklin
Lakes, NJ, USA) or ESBL Etest (bioMerieux) according to
the manufacturers’ instructions.
Determination of ESBL genotype
The infecting isolates from all patients, and follow-up isolates
from patients for which we found the ESBL production in a
different species and/or additional strain were subjected to a
real-time minor groove binder-probe based PCR for typing of
blaCTX-M to the phylogenetic subgroups [15]. CTX-M-negative
isolates were subjected to Check-point MDR CT102 DNA
microarray to detect blaTEM and blaSHV variants [16].
Escherichia coli phylogenetic groups
Phylogrouping of E. coli was based on triplex PCR (chuA, yjaA,
TspE4.C2) [17], and was only carried out with the infecting
isolates.
Identiﬁcation of O25b-ST131
Infecting isolates of E. coli were analysed with an O25b-ST131
allele-speciﬁc PCR assay of the pabB gene according to
Clermont et al. [18].
Epidemiological typing with pulsed-ﬁeld gel electrophoresis
Epidemiological typing of E. coli and K. pneumoniae isolates
using pulsed ﬁeld gel electrophoresis (PFGE) was performed
according to the PulseNet protocol for E. coli O157:H7 [19],
using XbaI for restriction of DNA. Isolates were considered
related if the PFGE patterns had a similarity index of >0.90
(Dice co-efﬁcient; corresponding to a difference of at least
three bands) [20], and possibly related if the PFGE patterns
had a difference of four to six bands. With lower similarity
indices we classiﬁed the strain as distinct from the original
strain.
Screening for virulence factors with multiplex PCR
The infecting E. coli isolates were screened for virulence
factors characteristic of uropathogenic E. coli with multiplex
PCR, using primers to detect genes encoding type 1 ﬁmbriae
(ﬁm) and p-ﬁmbriae, also known as pili associated with
pyelonephritis (pap): ﬁmH, ﬁmAMT78, papAH, papC, papEF,
papG, papG I, papG II and papG III [21].
PCR-based replicon typing
The infecting isolates from all patients, and follow-up isolates
from patients for which we found the ESBL production in a
different species and/or additional strain were subjected to a
PCR-based replicon typing previously described by Carattoli
et al. [22].
Statistics
Clinical data were extracted from patient questionnaires and
medical records. Patient- and strain-related factors were
compared for carriers and non-carriers at 12 months using
GRAPHPAD Software and STATA 11.0. Categorical variables were
compared using chi-squared test or Fisher’s exact test for
categorical data. Student’s t-test was used for continuous data.
Multivariate analysis was performed by logistic regression.
Exposure variables with a p-value <0.1 in univariate analyses
were included in the multivariate model.
The study was approved by the research ethics committee
in Stockholm, Sweden (Recordal: 2008/2:7).
Results
ESBL detection and epidemiological typing
After 1 month, 51/61 (84%) patients were EPE carriers, this
number was 36/61 (66%) after 3 months, 31/61 (55%) after
6 months and 26/61 (43%) after 12 months. At 12 months,
21% of the EPE carriers had one or several negative faecal
samples during follow up. During follow up the ESBL produc-
tion was found in a different bacterial species on seven
occasions or a novel strain of E. coli or K. pneumoniae on 20
occasions in a total of 17 patients. The results from the ESBL
detection and epidemiological typing (PFGE) are displayed in
Fig. 1. Fig. 1(a) shows data for carriers at 12 months and
Fig. 1(b) shows data for non-carriers.
ESBL genotyping
CTX-M-grouping of all retrievable clinical isolates (E. coli
n = 49, K. pneumoniae n = 7) showed that 38/56 (68%)
belonged to CTX-M-gr.-1, 13/56 (23%) to CTX-M-gr.-9. and
1/56 (2%) to CTX-M-gr.-8 or-25. Two patients of 56 (4%)
produced sulfhydryl variable (SHV) ESBLs and two had an ESBL
phenotype but no conﬁrmed genotype. In 10/17 patients, for
whom the ESBL production was found in a new species or
strain during the course of carriage, we found another
CTX-M-group than in the infecting strain in one or several
of the follow-up faecal samples (Fig. 2).
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Escherichia coli phylogenetic groups
Most of the clinical E. coli isolates belonged to phylogroup B2
(n = 19), followed by D (n = 15), A (n = 10) and B1 (n = 5).
Identiﬁcation of O25b-ST131
The pabB PCR (marker of ST131) was positive in 14/49 cases,
all B2 isolates.
Screening for virulence factors
Most E. coli isolates were positive for ﬁmH (n = 48), ﬁmAMT78
(n = 35) or both (n = 33). Six isolates were positive for ﬁmH
and ﬁmAMT78 as well as several genes encoding P ﬁmbriae
(papAH, papC, papEF, papG and papGII). Of these, only two
were derived from patients with prolonged carriage.
PCR-based replicon typing
The most frequent replicon content among the clinical isolates
of all patients was FrepB (n = 46) followed by FIA (n = 29) and
FIB (n = 27). Seventeen isolates contained both FIA and FIB
replicons. Eight isolates were positive for HI1 and I1, two for
N and one was positive for A/C and P, respectively. When
examining the isolates from the 17 patients in which ESBL
(a) (b)
FIG. 1. Extended spectrum b-lactamase (ESBL) -producing strains during follow up. Overview of the duration and dynamics of faecal carriage of
ESBL-producing Enterobacteriaceae (EPE). (a) Results of cultures and pulsed ﬁeld gel electrophoresis (PFGE) for those who were carriers at
12 months, (b) results for non-carriers. Each row shows the results for one patient. The symbols represent the species and strains where ESBL was
detected in the infecting isolate and in faeces at 1, 3, 6 and 12 months.
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production was found in a different species (n = 7) and/or a
novel strain of E. coli (n = 17) during follow up compared with
the beginning of the study, we detected an identical combi-
nation of replicons in both the original and the new strains in
only four cases. The results of the plasmid characterization are
shown in Fig. 2.
Patient factors and strain factors of the infecting isolate in
relation to duration of carriage
Phylogenetic group B2 occurred more frequently in E. coli
strains found in carriers at 12 months than among non-car-
riers (12/23 (52%) versus 6/26 (23%), p 0.04), which was also
the case for CTX-M-gr.-9 (10/25 (40%) versus 3/31 (10%),
p 0.01). Initial bloodstream infection was more common
among patients who were later found to be carriers at
12 months than among patients that were not (6/26 (23%)
versus 1/35 (3%), p 0.04). The frequencies of the various
patient and strain factors in relation to the duration of EPE
carriage are shown in Table 2. Bloodstream infection, phylo-
group B2 and CTX-M-gr.-9 were included in a logistic
regression model. Phylogroup B2 and CTX-M-gr.-9 were
associated with being a carrier at 12 months (OR4.3, 95% CI
1.1–16.3 and OR 6.4, 95% CI 1.3–30.9, respectively) whereas
bloodstream infection was no longer associated with pro-
longed carriage in the adjusted analysis (OR 4.7, 95% CI 0.4–
50.1).
Discussion
Our main ﬁnding was that faecal carriage of EPE often persists
1 year after infection, and that prolonged carriage is associated
with E. coli phylogroup B2 and ESBL CTX-M-gr.-9. Phylogroup
B2 is strongly associated with high virulence, and our ﬁndings
indicate that strain virulence could be an important factor also
for persistence of ESBL-producing E. coli in the intestinal
microbiota. However, we did not ﬁnd any differences in the
presence of the uropathogenetic virulence factors pap and ﬁm
genes between carriers and non-carriers, neither were there
any associations between the virulence genes and E. coli
phylogroups. Almost all infectious E. coli isolates were positive
for ﬁmH and ﬁmAMT78 genes, probably reﬂecting that these
isolates are virulent and mostly uropathogenic by deﬁnition.
CTX-M-gr.-1 includes the CTX-M-15 enzyme associated with
the highly virulent international clone ST131 and indirectly to
phylogroup B2, whereas CTX-M-gr.-9 has less frequently been
associated with such virulent clones. Previous studies
demonstrate that virulence of E. coli ST131 is related with
the strain and not with the presence of blaCTX-M-15 [23]. Of the
11 CTX-M-gr.-9 E. coli isolates, nine belonged to phylogroup
B2 (n = 4) or D (n = 5) isolates. The distribution of
CTX-M-groups in this study reﬂects the molecular epidemi-
ology of EPE in Sweden [24–26].
!!
Infecting
Patient isolate(s) 1 month 3 months 6 months 12 months
1       FrepB       -       FIA, FIB, I1, FrepB       FIA, FIB, FrepB       FIA, FIB, FrepB
2       FIA, FIB       FIA, FIB       FIA, FIB       FIA, FIB FIA, FIB
4       FIB, FrepB       FIB, FrepB          -       FIA, FIB, FrepB          FIA, FIB, FrepB         -       FIA, FIB, FrepB         FIA, FIB, FrepB       FIA, FrepB
8       FIA, FIB, FrepB       FIB, FrepB       FIA, FIB, FrepB          FIA, FIB, FrepB       FrepB       FIB, FrepB
10       FrepB       FIA, FrepB       FIA, FrepB       FIA, FrepB       FIA, FrepB         FIB, I1, FrepB
18       FIA, FrepB       FIA, FrepB          F1A, FIB, FrepB       FIA, FrepB          FIA, FIB, FrepB       FIA, FIB, FrepB       FIA, FrepB
19       FIA, FrepB       FIA, FrepB ns       FIA, FrepB          FIB, I1, FrepB       FIB, I1
21       FIB, FrepB       FIB, FrepB          FIA       -       -       FIB
22       FrepB       I1, FrepB ns       I1
23       FIB, FrepB       FIA, FIB, FrepB       FIB, FrepB
26       -       FIA, FrepB       FIA, I1         FrepB                    FIA, FIB, I1, FrepB        -
32       FIA, FIB       FIA, FIB       FIA, FIB, FrepB
33       -       FIB, FrepB          FrepB       FrepB       -
42       FrepB         FIA       FrepB         FIA, FIB              -          FIA, FIB, FrepB         FIA, FIB, FrepB       FIA, FIB, FrepB
44       FIA, FIB, HI1, I1       FIB, I1       FIA, FIB, FrepB
49       FIB, FrepB       FrepB          -       FIA, FIB, FrepB       FIA, FIB, FrepB
52       FIA, FIB, FrepB       FIB, FrepB          -       FIA, FIB, FrepB       FIA, FIB, FrepB
       E. coli, third strain, CTX-M-gr.-1
       E. coli, first strain, CTX-M-gr.-1        E. coli, third strain, CTX-M-gr.-9
       E. coli, first strain, CTX-M-gr.-9        E. coli, fourth strain, CTX-M-gr.-9
       E. coli, first strain, ESBL-phenotype, no confirmed genotype        E. coli, fifth strain, CTX-M-gr.-9
       E. coli, second strain, CTX-M-gr.-1        K. pneumoniae, first strain, CTX-M-gr.-1
       E. coli, second strain, CTX-M-gr.-9        K. pneumoniae, first strain, CTX-M-gr.-9
       E. coli, second strain, TEM        K. pneumoniae, second strain, CTX-M-gr.-1
       E. coli, second strain, ESBL-phenotype, no confirmed genotype        No PFGE- or CTX-M-typing result
Fecal isolates
Patients with ESBL-production detected in a new species and/or an additional strain during follow-up
!!!!!!!!!!!!!!!!!!!!
FIG. 2. CTX-M-groups and replicon types of extended spectrum b-lactamase (ESBL) -producing strains during follow up. Overview of the patients
for whom we found the ESBL production in a new species or strain during follow up. Each row shows the results of the cultures, pulsed ﬁeld gel
electrophoresis (PFGE), CTX-M grouping and PCR-based replicon typing for one patient. The symbols represent the species and strains where ESBL
production was found as well as the CTX-M-type. The replicon types of each strain can be found next to the symbol.
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In accordance with previous data [6], we show that negative
faecal samples within the ﬁrst year after ESBL infection do not
imply elimination of carriage. Most likely EPE persists in the gut
but in low numbers compared with susceptible Enterobacte-
riaceae in the intestinal microbiota, for which reason they are
not detected by routine methods. Ecological disturbances
caused by, for example, antimicrobial treatment on a later
occasion may promote overgrowth of the resistant bacteria
[27]. However, we found no correlation between antibiotic
consumption during the follow up and a shift from negative to
positive faecal samples. Neither were speciﬁc agents nor the
number of received antimicrobials associated with prolonged
carriage.
In 28% of the patients we found the ESBL production in
another or additional species and/or strain of E. coli or
K. pneumoniae during the follow up than at the beginning of
the study. This ﬁnding was more frequent among carriers at
12 months than non-carriers; supporting the hypothesis that
persisting carriage is linked to transfer of ESBL genes by
plasmids from transient to resident strains in the normal
intestinal microbiota. However, ten of these patients had a
new CTX-M-group in one or several of the follow-up samples.
These patients were probably colonized with several strains
producing ESBL of different genotypes at the beginning of the
study. Either all strains were not present in all faecal samples
or we were unable to distinguish these as unique strains when
selecting colonies from the screening plates. It cannot be
excluded that a new EPE was acquired during the follow up.
Since we have limited Swedish prevalence data on EPE carriage
in the community, it is difﬁcult to calculate the risk of being
re-colonized. However, with <3% of ESBL producers among
clinical isolates of E. coli and K. pneumoniae [28–30] we ﬁnd
this less likely, provided that there had been no new exposure
to risk factors.
As previously reported [10] we commonly detected
plasmids belonging to the IncF group, especially FrepB, FIA
and FIB. These plasmids are frequently found in both EPE and
non-EPE [12]. Their presence in two different ESBL-producing
strains from the same patient does not conﬁrm that an IncF
plasmid transferred the ESBL gene. Further, isolates frequently
have several plasmids, which may have multiple replicons. In 4/
17 of the patients with ESBL production in a different strain
and/or species we found the same replicon content of the ﬁrst
and at least one of the new strains (Fig. 2). However, we did
not establish a speciﬁc link between ESBL genes and replicons.
The main limitation of this study is the fairly small number of
patients. However, the mean age (p 0.87), sex (p 0.48) and
culture material (p 0.39) did not differ from the total group of
patients diagnosed with EPE infection during recruitment,
indicating that the results are generalizable. However, there
was a difference in the level of care (p 0.001), with no patients
from long-term care facilities included. These patients most
likely would have had a prolonged carriage compared with the
patients included in the study [6]. The quality of the
self-collected samples, transportation time and the detection
levels used by the laboratory may also have affected the
results. Collecting more than one sample at each time point or
using enrichment techniques might have given a higher rate and
TABLE 2. Comparison of patient and strain factors of the infecting isolate between extended spectrum b-lactamase carriers and
non-carriers 12 months after extended spectrum b-lactamase-producing Enterobacteriaceae infection
Variable
Carriers at 12 months n
(%)




Sex and age Women 14 (54) 21 (60) 0.8
Median age (years) 63 60 0.9
Type of infection Urinary tract infection 24 (92) 30 (86) 0.7
Bloodstream infectiona 6 (23) 1 (3) 0.04
Previously described risk factors for acquisition of
EPE
Previous antimicrobialb 10 (42) 16 (47) 0.8
Hospital stayb 13 (52) 14 (41) 0.4
Travel abroadb 11 (31) 20 (60) 0.3
Abnormalities in urinary tract 5 (20) 8 (24) 0.76
Urinary catheterb 9 (36) 12 (55) 1.0
Antimicrobial treatmentc Carbapenem treatment 5 (19) 2 (3) 0.15
CIP + TMP + TSU 9 (39) 11 (52) 0.8
NIT + MEC 7 (30) 11 (52) 1.0
More than two antimicrobial agents 3(13) 5 (16) 1.0
More than three antimicrobial
agents
2 (9) 2 (6) 1.0
Strain factors Phylogroup B2 12 (52) 6 (23) 0.04
ST131 9 (39) 5 (19) 0.2
CTX-M-1-group 15 (60) 23 (74) 0.4
CTX-M-9-group 10 (40) 3 (10) 0.01
Fim 23 (100) 25 (96) 1
Pap 14 (7) 3 (12) 0.7
aBold face = p <0.05.
bSix months before ESBL infection.
cFor the original infection with ESBL-producing bacteria (not additional treatment during follow-up).
CIP, ciproﬂoxacin; EPE, extended spectrum b-lactamase-producing Enterobacteriaceae; ESBL, extended spectrum b-lactamase; MEC, mecillinam; NIT, nitrofurantoin; TMP,
trimethoprim; TSU, trimethoprim-sulphamethoxazole.
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diversity of ESBL-positive isolates. If anything, these limitations
would contribute to an underestimation of the carriage rates
at the various time-points.
In conclusion we show that faecal carriage of EPE strains
often persists 1 year after infection, and that prolonged
carriage might be associated with E. coli phylogroups B2 and
CTX-M-gr.-9, and may be linked to the transfer of plasmids
carrying ESBL genes from an infecting or transient strain to
resident strains of Enterobacteriaceae in the intestinal micro-
biota. Negative samples within the ﬁrst year do not imply
elimination of carriage. This knowledge may prove important
for limiting the spread of EPE in hospitals and long-term care
facilities.
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